Literature DB >> 3170030

Tumor necrosis factor alpha induces early morphologic and metabolic alterations in Friend leukemia cell tumors and fibrosarcomas in mice.

E Proietti1, F Belardelli, G Carpinelli, M Di Vito, D Woodrow, J Moss, P Sestili, W Fiers, I Gresser, F Podo.   

Abstract

Morphologic and metabolic studies have been carried out on Friend leukemia cell (FLC) tumors (grown in DBA/2 mice) or fibrosarcomas (grown in C3H/HeN or C3H/HeJ mice) shortly after peritumoral injection of recombinant mouse tumor necrosis factor (TNF) alpha. Marked vascular congestion and focal extravasation of erythrocytes were observed as soon as 1 hr after injection of either FLC tumors or fibrosarcomas with TNF. Focal areas of disaggregation of tumor cells were observed 1 hr after injection of TNF. Intraluminal thrombi (composed of degranulated platelets and fibrin) were detected 3 and 6 hr after TNF treatment, and were associated with areas of depletion of endothelial cell cytoplasm. To correlate these morphologic changes in the tumor with alterations in tumor metabolism, NMR spectroscopy and biochemical studies were undertaken on freshly dissected FLC tumors and fibrosarcomas shortly after injection of TNF. The earliest metabolic alterations observed after 1 hr in TNF-treated FLC tumors of fibrosarcomas were: (i) increase in the average intratumoral pH; (ii) decrease in the levels of ATP. These phenomena were not associated with a reduced glycolytic capacity of TNF-treated tumors as, at these early times after injection, the levels of lactic acid were virtually the same for TNF-treated or control treated tumors. Alterations in the levels of some products of phospholipid degradation (GroPCho, GroPEtn, GroP and Cho) also occurred in these tumors as early as 3 hr after TNF treatment. These metabolic changes were not observed in ascitic FLC tumors after TNF treatment. We suggest that TNF induces alterations in tumor blood vessels which subsequently lead to changes in tumor metabolism and tumor degeneration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3170030     DOI: 10.1002/ijc.2910420420

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

Review 1.  Tumor necrosis factor: an update on basic research and clinical applications.

Authors:  M Schleuning; R Munker
Journal:  Klin Wochenschr       Date:  1990-09-03

2.  Expression of thrombomodulin in astrocytomas of various malignancy and in gliotic and normal brains.

Authors:  M Maruno; T Yoshimine; T Isaka; R Kuroda; H Ishii; T Hayakawa
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

3.  Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour.

Authors:  R A Maas; D H Van Weering; H F Dullens; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases.

Authors:  V Ciolli; L Gabriele; P Sestili; F Varano; E Proietti; I Gresser; U Testa; E Montesoro; D Bulgarini; G Mariani
Journal:  J Exp Med       Date:  1991-02-01       Impact factor: 14.307

5.  Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy.

Authors:  M E Pisanu; A Ricci; L Paris; E Surrentino; L Liliac; M Bagnoli; S Canevari; D Mezzanzanica; F Podo; E Iorio; R Canese
Journal:  Br J Cancer       Date:  2013-12-12       Impact factor: 7.640

6.  Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis.

Authors:  S de Kossodo; R Moore; S Gschmeissner; N East; C Upton; F R Balkwill
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.